| 01st week of 2011 patent applcation highlights part 30 |
| Patent application number | Title | Published |
|---|
| 20110002901 | BACTERIAL STRAIN HAVING ANTI-ALLERGIC ACTIVITY, AND BEVERAGE, FOOD AND ANTI-ALLERGIC AGENT COMPRISING CELL OF THE BACTERIAL STRAIN - It is an object of the present invention to provide a bacterial strain belonging to | 2011-01-06 |
| 20110002902 | INHIBITOR FOR BLOOD PHOSPHORUS LEVEL ELEVATION - The present invention provides an inhibitor for blood phosphorus level elevation comprising a lactic acid bacterium as an active ingredient. The inhibitor for blood phosphorus level elevation of the present invention is highly safe, is readily administerable, and can sufficiently inhibit a blood phosphorus level elevation. | 2011-01-06 |
| 20110002903 | IMMUNOGENIC CONTROL OF TUMOURS AND TUMOUR CELLS - The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a tumour-associated antigen and a redox motif such as C—(X)2-[CST] or [CST]-(X)2-C in the treatment of a tumour or in the treatment or prevention of a tumour relapse, and in the manufacture of medicaments therefore. | 2011-01-06 |
| 20110002904 | SYNOVIAL VILLI FOR USE WITH TISSUE ENGINEERING - Synovial villi derived explants and related surgical tools used to repair or prevent damage to injured or diseased tissue, including connective tissue. The tools including a harvesting tool for selectively harvesting synovial villi from the joint of patient and a delivery tool having a bulbous end for delivering the synovial villi derived explants while reducing damage to surrounding tissue. | 2011-01-06 |
| 20110002905 | COMPOSITIONS OF FAT-SOLUBLE ACTIVE INGREDIENTS CONTAINING PROTEIN-POLYSACCHARIDE CONJUGATES - The present invention relates to compositions containing one or more proteins, one or more polysaccharides and one or more fat-soluble active ingredients and their use for the enrichment, fortification and/or coloration of food beverages, animal feed and/or cosmetics. | 2011-01-06 |
| 20110002906 | Purification and Isolation of Recombinant Oxalate Degrading Enzymes and Spray-Dried Particles Containing Oxalate Degrading Enzymes - The present invention comprises methods and compositions for the reduction of oxalate in humans, and methods for the purification and isolation of recombinant oxalate reducing enzyme proteins. The invention provides methods and compositions for the delivery of oxalate-reducing enzymes in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions. | 2011-01-06 |
| 20110002907 | Methods, Systems, Compositions And Dosage Forms For Diagnosing And Treating Male Infertility - Methods and systems are provided for diagnosing male infertility relating to inadequate production of phosphatidic acid and are complementary to the routine tests, assessing sperm count, motility, viability, head morphology, and white blood cell count. Additional therapeutic methods, compositions and dosage forms are provided for treating male infertility that is related to inadequate production of phosphatidic acid. Such therapeutic approaches involve the use of phosphatidic acid or at least one of its precursors in the sperm intracellular signaling pathway. | 2011-01-06 |
| 20110002908 | TREATMENT OF A-GALACTOSIDASE A DEFICIENCY - The invention provides methods of treating α-galactosidase A deficiency. Dosage forms, methods of administration, and methods of analyzing human α-galactosidase A are also included. | 2011-01-06 |
| 20110002909 | METHOD, COMPOSITION, AND ARTICLE OF MANUFACTURE FOR PROVIDING ALPHA-1 ANTITRYPSIN - The present invention provides a method for providing alpha-1 antitrypsin (α1-AT) to a subject, in particular a method for treating or preventing a disorder or disease associated with α1-AT deficiency in the subject, wherein the method comprises providing, subcutaneously, a therapeutically or prophylactically effective amount of α1-AT to the subject. Also provided is a composition and article of manufacture comprising α1-AT, in particular a formulation suitable for subcutaneous administration of α1-AT. | 2011-01-06 |
| 20110002910 | THERAPEUTIC AGENTS COMPRISING PRO-APOPTOTIC PROTEINS - The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-inducing factor, such as granzyme B, granzyme A, or Bax. | 2011-01-06 |
| 20110002911 | METHOD FOR FERMENTING NATURAL MATERIALS WITH SALT AND FERMENTED EXTRACTS PREPARED THEREFROM - The present invention relates to a method for fermenting natural products with salt and fermented extracts prepared thereby. The method comprises: adding a predetermined amount of salt to at least one of natural products, including medicinal herbs and cereals; naturally fermenting the salted material; and extracting the fermented salted material with a solvent. Accordingly, the method can prevent the growth of various bacteria, including putrefactive bacteria, | 2011-01-06 |
| 20110002912 | COMPOSITION - The present invention relates to a composition for improving stem cell integration. The present invention also relates to a method of improving stem cell integration and kits for improving stem cell integration. | 2011-01-06 |
| 20110002913 | USE OF INTERLEUKIN-4 ANTAGONISTS AND COMPOSITIONS THEREOF - Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities. | 2011-01-06 |
| 20110002914 | HYBRID TETNUS TOXOID PROTEINS THAT MIGRATE RETROGRADELY AND TRANSYNAPTICALLY INTO THE CNS - The non-toxic proteolytic C fragment of tetanus toxin (TTC peptide) has the same ability to bind nerve cells and be retrogradely transported through a synapse as the native toxin. A hybrid protein encoded by the LacZ-TTC gene fusion retains the biological functions of both proteins in vivo, i.e. retrograde transynaptic transport of the TTC fragment and βgal enzymatic activity. After intramuscular injection, enzymatic activity can be detected in motoneurons and connected neurons of brainstem areas. This strategy is useful for the delivery of a biological activity to neurons from the periphery to the central nervous system. Such a hybrid protein can also be used to map synaptic connections between neural cells. | 2011-01-06 |
| 20110002915 | RANDOM AND NON-RANDOM ALKYLENE OXIDE POLYMER ALLOY COMPOSITIONS - A polymeric material comprised of (i) at least one random copolymer comprised of ethylene oxide and one or more other alkylene oxide(s) and (ii) at least one non-random polymer comprised of one or more poly(alkylene oxide)s has been discovered. Preferably, it is a polymer alloy. Alkylene oxide homopolymers or block copolymers may be the non-random polymer. In a related discovery, an adhesive material can be made by suspending (a) particles in (b) a matrix of at least one poly(ethylene oxide) copolymer of ethylene oxide and propylene oxide, or a combination thereof. The handling characteristics may be adjusted for different utilities (e.g., from runny oil to hard wax). Applications include use as adhesive, cohesive, filler, lubricant, surfactant, or any combination thereof. In particular, the hard materials may be used for cleaning or waxing. | 2011-01-06 |
| 20110002916 | Plasmodium falciparum antigens and their vaccine and diagnostic applications - The invention concerns novel | 2011-01-06 |
| 20110002917 | Antibody constant domain regions and uses thereof - The invention provides recombinant protein (e.g., a recombinant antibody or soluble receptor) having (i) a binding domain capable of specific binding to an epitope (for example an antibody variable domains, a receptor, a growth factor, a cytokine, or a fragment of any of the foregoing which is capable of specifically binding the desired epitope) and (ii) an effector domain comprising a constant domain region which is derived from immunoglobulin of a first species which is a companion mammal, e.g. dog, cat, or horse, having engineered substitutions at one or more positions and having an altered interaction with one or more FcRs or other ligands, and optionally enhanced effector function, relative to the parent constant domain region. | 2011-01-06 |
| 20110002918 | METHODS OF TREATING DISEASED TISSUE - Treatment protocols for severe psoriasis include administering biologics, stopping all administration of the biologics after the severity of the psoriasis has reduced and has reached an equilibrium, mildness and/or a tolerable state of remission, and administering UV phototherapy. The biologics may include, for example, the biologics found in Amevive®, Enbrel®, Humira®, Raptiva®, and Remicade® and/or alefacept, etanercept, adalimumab, efalizumab, infliximab, and ustekinumab. The UV phototherapy may be repeated, for example daily, weekly, monthly, yearly, to keep the psoriasis in a mild state or in a tolerable state of substantial remission. Parameters for administering UV phototherapy may be determined based on skin tone, Fitzpatrick skin phenotype, the severity of the psoriasis, the area of exposure, and/or the MED. | 2011-01-06 |
| 20110002919 | ANTAGONISTS OF NEUROPILIN RECEPTOR FUNCTION AND USE THEREOF - The present invention relates to antagonists of neuropilin receptor fuction and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases. | 2011-01-06 |
| 20110002920 | COMBINATION CANCER IMMUNOTHERAPY WITH CO-STIMULATORY MOLECULES - Provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer by administering an effective amount of a soluble form of a co-stimulatory molecule from an antigen presenting cell and by reducing the activity of immunoregulatory T cells in the individual. Methods of reduction in the activity of immunoregulatory T cells involve removing them ex vivo or depleting or inactivating them in vivo. Also provided are cancer therapeutic compositions comprising a soluble form of a co-stimulatory molecule from an antigen presenting cell and an antibody specific for an intracellular antigen. | 2011-01-06 |
| 20110002921 | COMBINATION CANCER IMMUNOTHERAPY WITH CO-STIMULATORY MOLECULES - Provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer by administering an effective amount of a soluble form of a co-stimulatory molecule from an antigen presenting cell and by reducing the activity of immunoregulatory T cells in the individual. Methods of reduction in the activity of immunoregulatory T cells involve removing them ex vivo or depleting or inactivating them in vivo. Also provided are cancer therapeutic compositions comprising a soluble form of a co-stimulatory molecule from an antigen presenting cell and an antibody specific for an intracellular antigen. | 2011-01-06 |
| 20110002922 | CELL GROWTH INHIBITORS CONTAINING ANTI-GLYPICAN 3 ANTIBODY - Provided is a cell growth inhibitor that can be used for treating diseases based on abnormal cell proliferation, and in particular cancer. The cell growth inhibitor contains an anti-glypican 3 antibody as an active ingredient. | 2011-01-06 |
| 20110002923 | METHODS OF INHIBITING TUMOR GROWTH USING TTK ANTAGONISTS - The present invention relates to methods for treating TTK positive breast cancers or soft-tissue sarcomas in a mammalian subject by administering a therapeutically effective amount of a TTK antagonist. The invention also provides compositions comprising a TTK antagonist and a HER-2 antagonist, as well as methods of diagnosing a basal-like breast cancer and methods of determining the prognosis of a subject having a cancer by assessing expression of TTK in a tumor sample from a subject. | 2011-01-06 |
| 20110002924 | TWEAK RECEPTOR AGONISTS AS ANTI-ANGIOGENIC AGENTS - The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed. | 2011-01-06 |
| 20110002925 | Use of Anti-IL-20 Antibody for Treating Rheumatoid Arthritis and Osteoporosis - Treatment of rheumatoid arthritis and osteoporosis using an anti-IL-20 antibody 7E, and optionally, in combination with an etanercept polypeptide. | 2011-01-06 |
| 20110002926 | HEPATITIS C VIRUS ANTIBODIES - This invention relates to humanized antibodies and fragments thereof which bind to hepatitis C virus E2 protein and methods of their use. | 2011-01-06 |
| 20110002927 | ANTIGEN-BINDING POLYPEPTIDES AGAINST CARTILAGE DEGENERATION - The invention provides an antigen-binding polypeptide which is able to penetrate into the cartilage. The disclosed polypeptide, compositions and methods are suitable for the treatment, prevention and/or delay of progression of cartilage degeneration. | 2011-01-06 |
| 20110002928 | Uses of Mammalian Cytokine; Related Reagents - Provided are methods of treatment for inflammatory and autoimmune disorders of the metabolic system. Also provided are methods of diagnosis. | 2011-01-06 |
| 20110002929 | AMINO ACID SEQUENCES DIRECTED AGAINST RANK-L AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF BONE DISEASES AND DISORDERS - The present invention relates to amino acid sequences that are directed against RANK-L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes. | 2011-01-06 |
| 20110002930 | Activated T Cells - Provided are compositions comprising activated T cells and activated T cells armed with bispecific antibodies directed at cancer antigens which are poor responders to alloantigen, and methods of using the compositions to help engraftment and improve anti-tumor effects. | 2011-01-06 |
| 20110002931 | BISPECIFIC ANTIBODIES THAT BIND TO COMPLEMENT PROTEINS - The present disclosure relates to bispecific antibodies that can bind to two or more different epitopes. For example, the bispecific antibodies described herein can bind to two or more different proteins, wherein at least two of the proteins are selected from C5a, C5b, a cellular receptor for C5a (e.g., C5aR1 or C5L2), the C5b-9 complex, and a component or intermediate of terminal complement such as C5b-6, C5b-7, or C5b-8. The bispecific antibodies described herein are useful for, e.g., inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 complex) and/or C5a anaphylatoxin-mediated inflammation (e.g., C5a-mediated chemotaxis of inflammatory immune cells). Accordingly, the bispecific antibodies can be used in methods for treating a variety of complement pathway-associated disorders. | 2011-01-06 |
| 20110002932 | POLY-N-ACETYL GLUCOSAMINE (PNAG/dPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and | 2011-01-06 |
| 20110002933 | DR4 ANTIBODIES AND USES THEREOF - Death Receptor 4 (DR4) antibodies are provided. The DR4 antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the DR4 antibodies are also provided. | 2011-01-06 |
| 20110002934 | USES OF ANTI-CD40 ANTIBODIES - This invention relates to new uses of anti-CD40 antibodies in the treatment of diseases or conditions associated with neoplastic B-cell growth in particular use of anti-CD40 antibodies in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). The invention is particularly useful for the treatment of patients who have previously been administered (i) CHOP, (ii) the chimeric anti-CD20 monoclonal antibody rituximab, or (iii) combination therapy with CHOP and rituximab. | 2011-01-06 |
| 20110002935 | ANTIBODY PURIFICATION - The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained. | 2011-01-06 |
| 20110002936 | Anti-IL-6/IL-6R Antibodies and Methods of Use Thereof - This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic. | 2011-01-06 |
| 20110002937 | METHOD OF MAKING HYBRID CELLS THAT EXPRESS USEFUL ANTIBODIES - This invention relates to a novel hybridoma strategy that uses CD27+ B cells cultured in vitro to induce IgM to IgG class switch prior to fusion with a fusion partner. Hybridomas resulting from the fusion between CD27+ B cells and a fusion partner cell line and antibodies secreted from the hybridomas are included in the invention. | 2011-01-06 |
| 20110002938 | HEMATOPOIETIC CELLS EXPRESSING THE PROTEIN KRTCAP3 AND LIGANDS FOR THE PROTEIN KRTCAP3 - The present invention relates to ex vivo hematopoietic cells characterized by the expression of the protein KRTCAP3 on the surface of said cells, to methods for isolating said cells and to ligands for KRTCAP3. | 2011-01-06 |
| 20110002939 | MONOCLONAL ANTIBODY AND A METHOD THEREOF - The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1(D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types. | 2011-01-06 |
| 20110002940 | PATHWAYS INVOLVED IN ARTERIOGENESIS AND USES THEREOF - The present invention relates to nucleic acids and polypeptides encoded thereby, whose expression is modulated in a subject suffering from insufficient arteriogenic capacity. These nucleic acids are among other useful in methods for diagnosing insufficient arteriogenic capacity, treating a subject suffering from insufficient arteriogenic capacity and/or stimulating arteriogenic capacity and/or stimulating arteriogenesis. | 2011-01-06 |
| 20110002941 | Antibodies that Specifically Bind Hedgehog-Derived Polypeptides - The present invention provides two novel polypeptides, referred to as the “N” and “C” fragments of hedgehog, or N-terminal and C-terminal fragments, respectively, which are derived after specific cleavage at a G′CF site recognized by the autoproteolytic domain in the native protein. Also included are sterol-modified hedgehog polypeptides and functional fragments thereof. Methods of identifying compositions which affect hedgehog activity based on inhibition of cholesterol modification of hedgehog protein are described. | 2011-01-06 |
| 20110002942 | Engineered Anti-IL-23 Antibodies - Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. | 2011-01-06 |
| 20110002943 | USE OF ENTEROVIRUS FOR DIAGNOSTICS, TREATMENT AND PREVENTION OF DISEASE - The invention is based on the finding that enterovirus is present in body samples of patients with celiac disease. The invention opens up the possibility for using enteroviruses in diagnosing, preventing, treating and monitoring the treatment of celiac-related diseases. The invention relates to a method for diagnosing, treating and monitoring the treatment of a celiac-related disease. The invention also relates to the use of enteroviruses or components or antibodies thereof for producing a vaccine, and the use of anti-enterovirus compositions for preparing a pharmaceutical against said disease. | 2011-01-06 |
| 20110002944 | Compositions and Methods to Promote Neural Cell Growth - The instant invention provides methods and compositions for promoting neural cell growth by inhibiting myelin associated glycoprotein (MAG)-induced inhibition of axonal regeneration. The invention relates to methods for identifying agents that inhibit MAG-induced inhibition of neural cell growth. Methods for inhibiting myelin associated glycoprotein (MAG)-induced inhibition of neural cell growth in a patient, methods for treating or preventing a MAG-induced disease or disorder of the CNS or PNS, comprising the step of administering at least one of the compositions according to this invention are provided. The invention includes kits comprising one or more agents identified according to the invention. | 2011-01-06 |
| 20110002945 | Use of immunoglobulin heavy and light chains or fragments thereof to bind to aggregated amyloidogenic proteins - Subunits of antibodies, such as a light chain or a heavy chain, selectively bind to amyloid fibrils and oligomers. | 2011-01-06 |
| 20110002946 | Immunostimulatory Combinations - The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen. | 2011-01-06 |
| 20110002947 | LEPTOMYCIN DERIVATIVES - Leptomycin derivatives having a moiety, such as a sulfide or a disulfide, that can conjugate to a cell binding reagent such as an antibody are disclosed. The therapeutic use of such leptomycin derivative conjugates is also described; such conjugates have therapeutic use because they can deliver cytotoxic leptomycin derivatives to a specific cell population in a targeted fashion. | 2011-01-06 |
| 20110002948 | IDENTIFICATION OF A NUCLEIC ACID MOLECULE - This invention relates to the identification of a nucleic acid molecule. In particular, this invention relates to a method of using an oligonucleotide designed to a variable region of a nucleic acid molecule to identify A nucleic acid molecule. | 2011-01-06 |
| 20110002949 | VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE - The invention provides a method for the treatment of a patient having a more severe form of Alzheimer's disease (AD), where the severe form of AD is characterized by pathogenic deposits of amyloid beta peptide (Aβ), comprising the administration of an immunogenic fragment of Aβ capable of inducing an immune response in the form of antibodies to specific to the pathogenic deposits of Aβ and, in particular, to neurotoxic forms of Aβ including N-terminally truncated forms of Aβ. The invention further provides a method for selecting a suitable immunogenic fragment of Aβ for the treatment of a more severe form of AD. | 2011-01-06 |
| 20110002950 | PIG EDEMA DISEASE VACCINE - A technology for producing a pig edema disease vaccine at low cost and at high efficiency is developed. Specifically, a gene of a pig edema disease toxin protein (Stx2e protein) is efficiently expressed in plant cells to produce a plant vaccine for pig edema disease at low cost. An Stx2e protein including a secretory signal peptide derived from a plant added at an amino terminus is expressed in cells of a plant such as | 2011-01-06 |
| 20110002951 | Modified Leukotoxin Gene and Protein - The present invention provides nucleic acid sequences encoding a modified leukotoxin protein, wherein the modification comprises the removal of nucleic acid sequences encoding amino acids within hydrophobic transmembrane domains of full length leukotoxin protein, preferably from | 2011-01-06 |
| 20110002952 | FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF - Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including metabolic and inflammatory and immune diseases or disorders, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which: Z is heterocyclo or heteroaryl; -A is a 5- to 8-membered carbocyclic ring or a 5- to 8-membered heterocyclic ring; B1 and B2 rings are pyridyl rings, wherein the B1 and B | 2011-01-06 |
| 20110002953 | USE OF IMMIDAZOQUINOLINAMINES AS ADJUVANTS IN DNA VACCINATION - The present invention relates to the use of a 1H-imidazo[4,5-c]quinolin-4-amine derivative as an adjuvant for use with nucleic acid vaccination. | 2011-01-06 |
| 20110002954 | RHOC-BASED IMMUNOTHERAPY - The present invention relates generally to the field of prophylaxis and therapy of metastatic cancer. In particular there is provided a protein; Ras Homology gene family, member C (RhoC) or peptide fragments thereof that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to use of RhoC or peptides derived thereof or RhoC specific T-cells for treatment of metastatic cancer. Hence, the invention in one aspect relates to RhoC specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. Also the use of RhoC and immunogenic peptide fragments hereof in cancer treatment, diagnosis and prognosis is provided. | 2011-01-06 |
| 20110002955 | ANTI-OBESE IMMUNOGENIC HYBRID POLYPEPTIDES AND ANTI-OBESE VACCINE COMPOSITION COMPRISING THE SAME - Disclosed is an immunogenic hybrid polypeptide for the prevention and treatment of obesity, in which a mimetic peptide of a B cell epitope of apolipoprotein B-IOO; a rabies virus helper T cell epitope or hepatitis B virus surface antigen helper T cell epitope and a C-terminal peptide fragment of mouse apolipoprotein Cu or a mimetic peptide of a B cell epitope of apolipoprotein B-100 are fused to each other in that order in the direction from the N terminus to the C terminus thereof. Also, a vaccine composition for the prevention and treatment of obesity, comprising the immunogenic hybrid polypeptide is disclosed, along with a polynucleotide encoding the immunogenic hybrid polypeptide, a recombinant expression vector carrying the polynucleotide, a host cell anchoring the recombinant expression vector, and a method for producing the immunogenic hybrid polypeptide by culturing the host cell transformed with the recombinant expression vector. | 2011-01-06 |
| 20110002956 | MUTANT HUMAN CD80 AND COMPOSITIONS FOR AND METHODS OF MAKING AND USING THE SAME - Improved vaccines and methods of using the same are disclosed Immunosuppressive compositions for treating individuals who have autoimmune diseases or transplants and methods of using the same are disclosed. | 2011-01-06 |
| 20110002957 | HAPTEN-CARRIER CONJUGATES FOR TREATING AND PREVENTING NICOTINE ADDICTION - Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction. | 2011-01-06 |
| 20110002958 | Alphavirus Vectors for Respiratory Pathogen Vaccines - Described herein are compositions and methods for stimulating an immune response to one or more proteins derived from one or more respiratory pathogens. In particular, the invention relates to alphavirus replicons, alphavirus vector constructs, and alphavirus replicon particles expressing one or more antigens derived from one or more respiratory pathogens, as well as to methods of making and using the immunogenic compositions. | 2011-01-06 |
| 20110002959 | Vaccine Production For Pathogenic Bird Viral Diseases - The present invention is an improved method for the production of vaccines to transmittable viral pathogens where the virus is pathogenic to the chicken embryos. Bird embryos are selected for vaccine production from wild and domestic birds, and preferably waterfowl, that have increased resistant to the viral pathogen. The invention is useful for native and engineered viruses. | 2011-01-06 |
| 20110002960 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS - Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided. | 2011-01-06 |
| 20110002961 | Interleukin 12 paracrine gene delivery enhanced CTL immunotherapy - A method of treating a patient with a disease wherein the patient contains diseased cells which cells contain antigens for identification and which cells are capable of presenting at least part of said antigen on their surface by an HLA class I (or equivalent) molecule, the method comprising administering to the patient a therapeutically effective amount of either antigen presenting cells which have been gene delivered with the interleukin 12 (IL-12) gene plus a relevant antigen. In a related set of claims said method refers to the administration to a patient of therapeutic levels of cytotoxic T lymphocytes (CTL) which recognize at least part of said antigen when presented by an HLA class I (or equivalent) molecule on the surface of a cell and which these CTL were stimulated by the antigen presenting cells, mentioned in the first section, which have been gene delivered with the interleukin 12 (IL-12) gene plus a relevant antigen. | 2011-01-06 |
| 20110002962 | Immunogenic PcpA Polypeptides and Uses Thereof - Provided herein are compositions and methods for eliciting an immune response against | 2011-01-06 |
| 20110002963 | COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GLIOBLASTOMA (GBM) AND OTHER CANCERS - The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas. | 2011-01-06 |
| 20110002964 | Methods for cancer treatment using stem cells - Various embodiments of the invention provide methods of treating cancer. Many embodiments provide methods of treating cancer using stem cells. In one embodiment the method comprises removing cancer cells from a patient and culturing the cancer cells in the presence of stem cells under conditions such that the stem cells differentiate into stem cell-derived cancer cells (SCDCC) which can comprise stem cell derived non-invasive and/or invasive cancer cells. An amount of the SCDCC is introduced into the patient sufficient to induce the patient's immune system to produce antibodies which inhibit or destroy the patient's cancer cells. The SCDCC may also be genetically modified to produce various immune stimulating proteins which enhance the patient's immune response to the cancer cells and improves the efficacy of the SCDNIC in treating the patient's cancer. | 2011-01-06 |
| 20110002965 | IMMUNOMODULATING COMPOUNDS AND RELATED COMPOSITIONS AND METHODS - Provided herein are compounds, compositions and methods for balancing a T-helper cell profile and in particular Th1, Th2, Th17 and Treg cell profiles, and related methods and compositions for treating or preventing an inflammatory condition associated with an imbalance of a T-helper cell profile. | 2011-01-06 |
| 20110002966 | Vaginal Suppository System and Method - A vaginal suppository system contains a formulation comprising active and inactive ingredients, which active ingredients may be nutraceuticals, herbs, vitamins, minerals and other bioactive agents. In an embodiment, the active ingredients comprise Oak gall, true unicorn root, bitter orange peel, tropical almond, heartsease, and zinc oxide. The formulation may be contained in a soluble encapsulation or a suspension for administration of the formulation in a vagina. A method of preparing a vaginal suppository system and a method of treating a vagina with a formulation comprising active and inactive ingredients are also disclosed. | 2011-01-06 |
| 20110002967 | Methods of Transdermally Administering an Indole Serotonin Receptor Agonist and Transdermal Compositions for Use in the Same - Methods of transdermally delivering a therapeutic amount of an indole serotonin receptor agonist to an individual in need thereof, e.g., to provide a therapeutic level of an indole serotonin receptor agonist to an individual in need thereof, are provided. Also provided are transdermal formulations of indole serotonin receptor agonists that find use in practicing the subject methods. | 2011-01-06 |
| 20110002968 | COSMETIC OR DERMATOLOGICAL COMPOSITION CONTAINING AN ORCHID EXTRACT, AND COSMETIC CARE METHOD USING SAID COMPOSITION - Cosmetic or dermatological compositions contain an orchid extract obtained from at least a part of the species | 2011-01-06 |
| 20110002969 | COSMETIC OR PHARMACEUTICAL COMPOSITIONS COMPRISING METALLOPROTEINASE INHIBITORS - Peptides of general formula (I): R | 2011-01-06 |
| 20110002970 | PROCESS FOR THE PREPARATION OF NANO ZINC OXIDE PARTICLES - A process for the preparation of nano zinc oxide particles comprising dissolving a zinc metal precursor in a solvent to obtain a first solution; dissolving a base in an alcohol to obtain an alkali solution; and adding the alkali solution to the first solution over a predetermined period of time to obtain nano zinc oxide particles in solution. | 2011-01-06 |
| 20110002971 | CERIA FOR USE AS AN ANTIMICROBIAL BARRIER AND DISINFECTANT IN A WOUND DRESSING - The present invention relates to protecting a human from an infection using a disinfecting agent as described herein and a method for use thereof, more particularly to a rare earth-containing device for protecting a wound and a method for use thereof. | 2011-01-06 |
| 20110002972 | NEUROENDOCRINE FACTORS FOR TREATMENT OF DEGENERATIVE DISEASES - The present invention is related to the use of a repellent factor and/or polypeptide for manufacturing of a pharmaceutical composition for treating a disease such as a degenerative disease in particular to the use of a SLIT3 or NETRIN1 protein therefore. The invention is further related to a polypeptide fragment of SLIT3, a pharmaceutical composition comprising the polypeptide and the use thereof. | 2011-01-06 |
| 20110002973 | MATERIALS AND METHODS FOR MINIMALLY-INVASIVE ADMINISTRATION OF A CELL-CONTAINING FLOWABLE COMPOSITION - The disclosed invention is based on the discovery that a cell-based therapy can be used to treat, ameliorate, manage and/or reduce the progression of clinical sequelae associated with vascular interventions or cardiovascular diseases, particularly occlusive thrombosis, restenosis, intimal hyperplasia, inflammation and vasodilation. The invention further benefits from the additional discovery that a heretofore undescribed implantable flowable composition is capable of sustaining a confluent population of sufficiently viable cells which can be effectively administered via a minimally-invasive surgical procedure without diminishing the clinical effectiveness or the viability of the cells. The disclosed invention can be used to treat vasculature as well as non-vascular tubular structures such as a fallopian tube. | 2011-01-06 |
| 20110002974 | RANDOM AND NON-RANDOM ALKYLENE OXIDE POLYMER ALLOY COMPOSITIONS - A polymeric material comprised of (i) at least one random copolymer comprised of ethylene oxide and one or more other alkylene oxide(s) and (ii) at least one non-random polymer comprised of one or more poly(alkylene oxide)s has been discovered. Preferably, it is a polymer alloy. Alkylene oxide homopolymers or block copolymers may be the non-random polymer. In a related discovery, an adhesive material can be made by suspending (a) particles in (b) a matrix of at least one poly(ethylene oxide) copolymer of ethylene oxide and propylene oxide, or a combination thereof. The handling characteristics may be adjusted for different utilities (e.g., from runny oil to hard wax). Applications include use as adhesive, cohesive, filler, lubricant, surfactant, or any combination thereof. In particular, the hard materials may be used for cleaning or waxing. | 2011-01-06 |
| 20110002975 | PREOPERATIVE TREATMENT OF POST OPERATIVE PAIN - A method of treating postoperative pain in a patient undergoing a surgery is described. The method is based on preoperative administration of a buprenorphine-containing transdermal dosage form. The dosage form can be administered to the patient, for example, 1-4 days prior to surgery. Alternative embodiments of the invention include subsequent transdermal dosage forms to treat the postoperative pain. | 2011-01-06 |
| 20110002976 | MEDICATED PATCH - Provided is a medicated patch containing a medicinal agent, an adhesive base material and a tackifier, where the medicinal agent is varenicline or a pharmaceutically acceptable salt thereof, the adhesive base material is a rubbery adhesive base material and the tackifier is a rosin-based tackifier selected from the group consisting of rosin, rosin derivatives and hydrogenated products of the foregoing, or a non-rosin-based tackifier selected from the group consisting of aliphatic hydrocarbon resins and alicyclic hydrocarbon resins, and when a non-rosin-based tackifier is added as the tackifier, a solubilizer for the medicinal agent is further added, the solubilizer containing an alcohol-based solubilizer having at least a solubility parameter of 20-35. | 2011-01-06 |
| 20110002977 | LIPOSOMAL PHARMACEUTICAL PREPARATION AND METHOD FOR MANUFACTURING THE SAME - The present invention relates to a liposomal pharmaceutical preparation containing a multivalent ionic drug, a process for the preparation of the liposomal pharmaceutical preparation, and a use thereof in the treatment of diseases, in which the liposome has a size of about 30-80 nm, and the phospholipid bilayer has a phospholipid with a Tm higher than body temperature, so that the phase transition temperature of the liposome is higher than the body temperature. | 2011-01-06 |
| 20110002978 | ENZYME PRODRUG CANCER THERAPY SELECTIVELY TARGETED TO TUMOR CELLS OR TUMOR VASCULATURE AND METHODS OF PRODUCTION AND USE THEREOF - Conjugates for use in an enzyme prodrug cancer therapy treatment are provided. | 2011-01-06 |
| 20110002979 | STYRENE MALEIC ANHYDRIDE BASED FORMULATION FOR MALE CONTRACEPTION AND PROSTATE CANCER - The invention provides a styrene maleic anhydride based synergistic formulation comprising styrene maleic anhydride [SMA] having lower molecular weight and styrene maleic anhydride [SMA] having higher molecular weight dissolved in DMSO, and being capable of preventing the prostate cancer as well as causing male contraception even when administered in smaller doses for one or two administrations in the life time and predominantly causing no or minimal side effects, and still being reasonably affordable by common man, and the formulation being capable of traveling along the vas deferens after causing male contraception in the vas deferens to the prostate gland and getting absorbed into the epithelial zone of the prostate gland. | 2011-01-06 |
| 20110002980 | VACCINES USING NUCLEIC ACID-LIPID COMPLEXES - This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, an infectious disease, or a condition associated with a deleterious activity of a self-antigen. Also disclosed are therapeutic compositions useful in such a method. | 2011-01-06 |
| 20110002981 | MCPIP Protection Against Cardiac Dysfunction - Disclosed herein are methods and compositions of treating a patient at risk of experiencing sepsis induced cardiac dysfunction. In exemplary examples, the method involves elevating MCPIP levels in a patient in need. Elevating MCPIP levels may involve direct administration (e.g. delivery of protein) or indirect administration (e.g. delivery vehicle capable of increasing expression of MCPIP). | 2011-01-06 |
| 20110002982 | LIPID CARRIER COMPOSITIONS WITH ENHANCED BLOOD STABILITY - Liposomes that contain at least 10 mol % of a negatively charged lipid coupled to a non-zwitterionic moiety are stable in the blood. Liposomes containing at least 1 mol % of such lipids may be frozen safely. | 2011-01-06 |
| 20110002983 | COMPOUND - The invention provides a compound (which can act as an adjuvant) of Formula I or Formula (II), wherein R | 2011-01-06 |
| 20110002984 | FORMULATIONS COMPRISING EXINE SHELLS - A formulation containing an active substance encapsulated within an exine shell of a naturally occurring spore, together with a protective additive which is also encapsulated within the exine shell. | 2011-01-06 |
| 20110002985 | ABUSE RESISTANT DRUGS, METHOD OF USE AND METHOD OF MAKING - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 2011-01-06 |
| 20110002986 | Stable Shellac Enteric Coating Formulation for Nutraceutical and Pharmaceutical Dosage Forms - The present invention relates to formulations for use as enteric coatings. More particularly, the present invention relates to a formulation comprising a blend of food grade ingredients that can be readily dispersed in water. This dispersion exhibits low viscosity and can easily be coated onto solid dosage forms through spraying and the like to provide an enteric coating on the solid dosage form. | 2011-01-06 |
| 20110002987 | Nicorandil Carriers with Enhanced Stability - The invention provides a carrier for nicorandil, which is preferably in form of a blister pack, comprising one or several dose blister pockets each containing at least one tablet of nicorandil, and at least one blister pocket containing a molecular sieve. | 2011-01-06 |
| 20110002988 | ORALLY RAPIDLY DISINTEGRATING TABLET COMPRISING IMIDAFENACIN - Provided herein is an imidafenacin-containing orally rapidly disintegrating tablet which is excellent in the photostability. | 2011-01-06 |
| 20110002989 | METHODS, DOSAGE FORMS AND KITS FOR ADMINISTERING ZIPRASIDONE WITHOUT FOOD - The present invention provides methods, dosage forms and kits for treating with an effective amount of ziprasidone a CNS disorder in a human when the human is in a fasted state. In one embodiment, the invention relates to a method for treating a CNS disorder in a human, which method comprises administering to the human in a fasted state, a solid oral dosage form comprising an amount of ziprasidone effective to treat said CNS disorder, wherein the area under the serum concentration versus time curve (AUC | 2011-01-06 |
| 20110002990 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROCODONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF - The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology. | 2011-01-06 |
| 20110002991 | PHENYLETHANOIC ACID, PHENYLPROPANOIC ACID AND PHENYLPROPENOIC ACID CONJUGATES AND PRODRUGS OF HYDROCODONE, METHOD OF MAKING AND USE THEREOF - The presently described technology provides phenylethanoic acid, phenylpropanoic acid, phenylpropenoic acid, a salt thereof, a derivative thereof or a combination thereof chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs or compositions of hydrocodone which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology. | 2011-01-06 |
| 20110002992 | N-SULPHONYLATED AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF - The present invention relates to N-sulfonylated amino acid derivatives, where an aryl radical is linked via the sulfonyl group N-terminally to the amino acid and a radical which comprises at least one imino group and at least one further basic group which represents an optionally modified amino, amidino or guanidino group is linked C-terminally via the carbonyl group. The invention likewise relates to processes for preparing these compounds and to their use, in particular as inhibitors of matriptase. | 2011-01-06 |
| 20110002993 | FILM COATED TABLETS CONTAINING DROSPIRENONE AS ACTIVE AGENT AND A METHOD FOR THE PREPARATION THEREOF - The invention relates to drospirenone containing film-coated tablet with improved resistance against the environmental influences, especially against atmospheric humidity. The invention further relates to a method for the preparation film-coated tablet cores whereby applying the active agent to the core may be accomplished with increased safety. | 2011-01-06 |
| 20110002994 | METHOD OF REGULATING THE TH17 PATHWAY AND ITS ASSOCIATED METABOLIC IMPACT - It is disclosed a method of immunomodulating an immune response in a subject comprising administering to a subject a malleable protein matrix (MPM), from fermented whey, in an amount effective to modulate the biological activity of Th17 cells, and its associated metabolic pathway, for a preventative or a therapeutic purpose of a variety of health applications in the field of immunity or obesity related diseases. | 2011-01-06 |
| 20110002995 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE - Provided is a pharmaceutical composition for the treatment and prevention of cardiac diseases, containing (a) a therapeutically effective amount of a compound represented by Formula 1 or 2 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof. | 2011-01-06 |
| 20110002996 | ACELLULAR TISSUE MATRICES MADE FROM ALPHA-1,3-GALACTOSE-DEFICIENT TISSUE - The invention provides acellular tissue matrices made from collagen-containing tissues of animals genetically modified so as to be deficient in the galactose 1,3-galactose epitope and methods of making and using such acellular tissue matrices. | 2011-01-06 |
| 20110002997 | PHOTOINITIATED TISSUE FILLER - Visible light-activated polymer cosmetic filler preparations useful in a variety of applications are provided. In some embodiments, the photo-activated polymer composition comprises a conventional polymeric material, such as HA, together with a modified, cross-linkable polymer, such as PEG or PEODA, to permit the formation of crosslinks within the polymer matrix in situ on exposure to a visible light source, such as an IPL device. The preparations provide for a more stabilized composition that is contourable during gelation. | 2011-01-06 |
| 20110002998 | PROCESS FOR THE PRODUCTION OF INSECTICIDE-MODIFIED BEAD MATERIAL COMPOSED OF EXPANDABLE POLYSTYRENE AND INSECTICIDE-MODIFIED MOLDINGS OBTAINABLE THEREFROM - A process for the production of insecticide-modified bead material composed of expandable polystyrene (EPS) by extrusion, encompassing the steps of a) mixing, in a mixer, to incorporate a blowing agent and at least one insecticide from the group of the phenylpyrazoles, chlorfenapyr and hydramethylnon into a polymer melt which comprises at least one polystyrene, based on a vinylaromatic monomer, b) discharging the polymer melt comprising blowing agent, and c) pelletizing the polymer melt comprising blowing agent. | 2011-01-06 |
| 20110002999 | Biopolymer System for Tissue Sealing - A tissue sealant for use in surgical and medical procedures for sealing the tissues of a living mammal is provided. The tissue sealant comprises a hydrogel which is formed by gelation of a premix disposed on the tissue to be sealed. The premix comprises alkylated chitosan or a gelatin, and a polybasic carboxylic acid or an oxidized polysaccharide, in an aqueous medium. The premix can also include a dehydrating reagent, a carboxyl activating reagent, or both. A specific use of the tissue sealant is in the repair of the dura mater after brain surgery to prevent leakage of cerebrospinal fluid. The tissue sealant may include a therapeutic or protective agent such as an antibiotic or an anti-inflammatory drug. | 2011-01-06 |
| 20110003000 | Transvaginal Delivery of Drugs - Drug delivery compositions which are suitable for transvaginal administration for the treatment of diseases and disorders of the urogenital tract are described. The drug delivery compositions are administered directly to the vagina using a convenient transvaginal application that deposits a very small volume of drug at the desired site for delivery. This method of administration reduces the systemic levels of the drugs and decreases the side effects which are associated with systemic administration. In the preferred embodiment, the compositions are in the form of a gel. The formulation is administered in volumes of less than or equal to 1 milliliter. In the preferred embodiment, the composition contains an antimuscarinc drug, such as oxybutynin. | 2011-01-06 |
